FDA approves non-combo hydrocodone product

Share this article:

Announced last Friday, Zohydro will become the first FDA-approved non-combination (not combined with analgesics like acetaminophen) and extended-release hydrocodone product.

The decision is particularly eyebrow-raising as only one day prior, the regulator issued a statement announcing it would aim to tighten the control of hydrocodone-combination products (like Vicodin) in an effort to reduce misuse and abuse by moving these products to Schedule II from Schedule III.

Schedule II drugs—part of the Controlled Substances Act—are classified as having a "high potential for abuse" and that abuse of those drugs could lead to "severe psychological or physiological dependence," under the Controlled Substances Act. Cocaine and methamphetamine, among others, are classified as Schedule II.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.